Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery

Biopharmaceutics and Drug Disposition

Volumn 23, Issue 7, 2002, Pages 293-300

  Gascon A R ^a   Campo, E ^b   Olea, E ^b   Hernandez R M ^a   Calvo, B ^a   Errasti, J ^b   Pedraz, J L ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Biliary surgery; Pefloxacin; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; PEFLOXACIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; BILIARY TRACT SURGERY; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CORE TEMPERATURE; DOSE RESPONSE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; ELECTIVE SURGERY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FEMALE; GALLBLADDER; HOSPITAL DEPARTMENT; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; PLASMA CLEARANCE; PREOPERATIVE TREATMENT; SPAIN; SPECIES DIFFERENCE; STAPHYLOCOCCUS EPIDERMIDIS; STEADY STATE; SUBCUTANEOUS TISSUE; SURGICAL INFECTION; SURGICAL WOUND; TISSUE CULTURE; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; AREA UNDER CURVE; CHOLECYSTECTOMY; COMMON BILE DUCT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PEFLOXACIN; TISSUE DISTRIBUTION;

EID: 0036799666     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.321     Document Type: Article

References (35)

1. Dellinger EP, PA Gross PA, Barret TL, Krause PJ, Martone WJ, McGowan Jr JE, Sweet RL, Wenzel RP. Quality standard for antimicrobial prophylaxis in surgical procedures. Clin Infect Dis 1994; 18: 422-427.
2. Gyssens IC. Preventing postoperative infections. Current treatment recommendations. Drugs 1999; 57: 175-185.
3. Lewis R, Graydon R, Marien B, Lloyd-Smith W, Wiegand F. Biliary bacteria, antibiotic use and wound infection in surgery of the gallbladder and common bile duct. Arc Surg 1987; 122: 44-47.
4. Ros Die E, Vidal Masso M, Morales OI, Rodríguez J, Galvez R. Bacteriología en la litiasis biliar. Factores interdependientes. Cir Esp 1983; 37: 8-14.
5. Mandel LA. Role of quinolones in surgical prophylaxis. Eur J Clin Microbiol Infect Dis 1992; 10: 368-377.
6. Gascón AR, Campo E, Hernández RM, Calvo B, Errasti J, Pedraz JL. Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery. Clin Drug Invest 1998; 15: 491-496.
7. Gonzales JP, Henwood JM. Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 37: 628-668.
8. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing: eighth informational supplement 1998; M 100-S8: 53-71.
9. Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microb 1991; 29: 533-538.
10. WINNONLIN: User's guide: Software for the Statistical Analysis of Nonlinear Models. Scientific Consulting: Cary, NC, 1995.
11. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics, (2nd edn.) Gibaldi M, Perrier D (eds), Marcel Dekker: New York, 1982; 409-417.
12. Fuchs PC, Barry AL, Jones RN, Thornsberry C. Tentative disk diffusion susceptibility interpretative criteria for pefloxacin. J Clin Microb 1986; 24: 448-450.
13. Phillips I, King A: Comparative activity of the 4-quinolones. Rev Infect Dis 1988; 10 (Suppl 1): S70-S76.
14. Toma E, Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. J Clin Microb 1995; 33: 1712-1715
15. Westphal JF, Brogard JM. Biliary tract infections. A guide to drug treatment. Drugs 1999; 33: 81-91.
16. Bergquist EJ, Murphey SA. Prophylactic antibiotics for surgery. Med Clin North Am 1987; 71: 357-368.
17. Levin S, Goodman L. Selected overview of nongynecologic surgical intra-abdominal infections. Am J Med 1985; 79 (Suppl. 5B): 146-156.
18. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokin 1995; 28: 143-160.
19. Marchbanks CR, McKiel JR, Gilbert DH, Robillard NJ, Painter B, Zinner SH, Dudley MN. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococus aureus in an in vitro model of infection. Antimicrob Agents Chemother 1993; 37: 1756-1763.
20. Forrest A, Nix DE, Ballow CH, Goss TF, Birgmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
21. Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual principles. II. The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994; 28: 863-868.
22. Madaras-kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627-632.
23. Schentag JJ, Nix DE, Forrest A, Adelman MH. AUIC-the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996; 30: 1029-1031.
24. Thomas A, Forrest JK, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely I11 patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527.
25. Preston SL, Drusano G, Berman AL, Fowler CL, Chow AT, Dornserif B, Reichl V, Natarajan J, Corrado M. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. J Am Med Assoc 1998; 279: 125-129.
26. Bergan T. Pharmacokinetics of the fluoroquinolones. In The Quinolones. (2nd ed), Andriole VT (ed.). Academic Press: London, 1998.
27. Lode H. Pharmacokinetics and clinical results of parenterally administered new quinolones in human. Rev Infect Dis 1989; 2 (Suppl. 5): S996-S1004.
28. Redington J, Ebert SC, Craig WA. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. Rev Infect Dis 1991; 13 (Suppl 10): S790-S799.
29. Thomas M. Antibiotics in bile. J Antimicrob Chemother 1983; 12: 419-422.
30. Bergan T. Pharmacokinetic parameters and characteristics relevant to antimicrobial surgical prophylaxis. Scand J Infect Dis 1990; 70: 31-5.
31. Keighley MRB, Drysdake RB, Quoraishi AH, et al. Antibiotics in biliary disease: The relative importance of antibiotic concentrations in the bile and serum. Gut 1976; 17: 495-500.
32. Gascón AR, Campo E, Hernández RM, Calvo B, Errasti J, Pedraz JL. Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery. J Clin Pharmacol 2000; 40: 869-874.
33. Baum ML, Anisch DS, Chalmers TC et al. A survey of clinical trials of antibiotic prophylaxis in colon surgery. Evidence against further use of no treatment controls. N Engl J Med 1981; 305: 795-799.
34. Polk Jr HC, López Mayor JF: Postoperative wound infection. A prospective study of determinant factors and prevention. Surgery 1979; 66: 97-103.
35. Kaiser AB. Antimicrobial prophylaxis in surgery. N Engl Med 1986; 315:1129-1138.